NASDAQ:RPTX

Repare Therapeutics News Headlines

$32.46
+1.68 (+5.46 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$30.07
Now: $32.46
$32.88
50-Day Range
$25.89
MA: $29.80
$33.62
52-Week Range
$21.45
Now: $32.46
$46.44
Volume145,302 shs
Average Volume153,669 shs
Market Capitalization$1.20 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Repare Therapeutics (NASDAQ RPTX) News Headlines Today

SourceHeadline
Repare Therapeutics (NASDAQ:RPTX) Upgraded by Zacks Investment Research to HoldRepare Therapeutics (NASDAQ:RPTX) Upgraded by Zacks Investment Research to Hold
marketbeat.com - March 17 at 3:50 AM
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Up to $30.78Repare Therapeutics (NASDAQ:RPTX) Shares Gap Up to $30.78
americanbankingnews.com - April 12 at 11:12 AM
Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day EventRepare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event
finance.yahoo.com - April 8 at 1:08 PM
Repare Therapeutics (NASDAQ:RPTX) Sees Unusually-High Trading VolumeRepare Therapeutics (NASDAQ:RPTX) Sees Unusually-High Trading Volume
americanbankingnews.com - April 8 at 11:30 AM
Repare Therapeutics (NASDAQ:RPTX) Trading 6.8% Higher Repare Therapeutics (NASDAQ:RPTX) Trading 6.8% Higher
americanbankingnews.com - April 5 at 3:10 PM
Repare Therapeutics Inc. (NASDAQ:RPTX) Given Average Recommendation of "Buy" by BrokeragesRepare Therapeutics Inc. (NASDAQ:RPTX) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 4 at 9:16 AM
Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4.9%Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4.9%
americanbankingnews.com - April 1 at 2:10 PM
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $30.93Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $30.93
americanbankingnews.com - March 24 at 11:38 AM
Repare Therapeutics (NASDAQ:RPTX) Trading Down 8%Repare Therapeutics (NASDAQ:RPTX) Trading Down 8%
americanbankingnews.com - March 23 at 12:45 PM
Repare Therapeutics (NASDAQ:RPTX) Trading 8.3% Higher Repare Therapeutics (NASDAQ:RPTX) Trading 8.3% Higher
americanbankingnews.com - March 22 at 3:28 PM
Valence Discovery to Support Repare Therapeutics on AI-Enabled Drug Discovery in Precision OncologyValence Discovery to Support Repare Therapeutics on AI-Enabled Drug Discovery in Precision Oncology
finance.yahoo.com - March 18 at 12:36 PM
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsRepare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 4 at 8:18 PM
Repare Therapeutics Announces March 2021 Virtual Investor Conference ParticipationRepare Therapeutics Announces March 2021 Virtual Investor Conference Participation
finance.yahoo.com - February 23 at 12:00 PM
Could The Repare Therapeutics Inc. (NASDAQ:RPTX) Ownership Structure Tell Us Something Useful?Could The Repare Therapeutics Inc. (NASDAQ:RPTX) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - February 9 at 5:07 PM
Repare Therapeutics to Present at Virtual Investor Conferences in JanuaryRepare Therapeutics to Present at Virtual Investor Conferences in January
finance.yahoo.com - January 4 at 9:38 AM
Repare Therapeutics Insiders Establish Automatic Securities Disposition PlansRepare Therapeutics Insiders Establish Automatic Securities Disposition Plans
finance.yahoo.com - December 31 at 7:32 PM
Repare Therapeutics Inc. (RPTX)Repare Therapeutics Inc. (RPTX)
realmoney.thestreet.com - December 30 at 11:30 PM
Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New TherapiesRepare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies
seekingalpha.com - December 30 at 6:30 PM
What Canada needs to do to build a world-class biotech sectorWhat Canada needs to do to build a world-class biotech sector
theglobeandmail.com - December 23 at 10:57 PM
Repare Therapeutics Inc Registered Shs OverweightRepare Therapeutics Inc Registered Shs Overweight
markets.businessinsider.com - December 17 at 11:09 PM
Repare Therapeutics Added to the NASDAQ Biotechnology IndexRepare Therapeutics Added to the NASDAQ Biotechnology Index
finance.yahoo.com - December 17 at 6:08 PM
Is RPTX A Good Stock To Buy Now?Is RPTX A Good Stock To Buy Now?
finance.yahoo.com - December 15 at 11:57 PM
Repare Therapeutics to Participate at the Piper Sandler 32nd Annual Virtual Healthcare ConferenceRepare Therapeutics to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
finance.yahoo.com - November 23 at 7:51 AM
Repare Therapeutics EPS beats by $0.06Repare Therapeutics EPS beats by $0.06
seekingalpha.com - November 13 at 8:07 PM
Repare Therapeutics Reports Third Quarter 2020 Financial Results and Operational HighlightsRepare Therapeutics Reports Third Quarter 2020 Financial Results and Operational Highlights
finance.yahoo.com - November 11 at 5:38 PM
Why Earnings Season Could Be Great for Repare Therapeutics (RPTX)Why Earnings Season Could Be Great for Repare Therapeutics (RPTX)
nasdaq.com - November 11 at 12:37 PM
Have Insiders Been Buying Repare Therapeutics Inc. (NASDAQ:RPTX) Shares?Have Insiders Been Buying Repare Therapeutics Inc. (NASDAQ:RPTX) Shares?
finance.yahoo.com - September 21 at 5:07 PM
Repare Therapeutics to Participate at Morgan Stanley Annual Global Healthcare ConferenceRepare Therapeutics to Participate at Morgan Stanley Annual Global Healthcare Conference
finance.yahoo.com - September 9 at 8:36 AM
Repare Therapeutics Reports Second Quarter 2020 Financial Results and Operational HighlightsRepare Therapeutics Reports Second Quarter 2020 Financial Results and Operational Highlights
finance.yahoo.com - August 13 at 8:05 PM
Repare Therapeutics IncRepare Therapeutics Inc
reuters.com - August 13 at 12:23 AM
Repare Therapeutics Inc. Common Shares (RPTX)Repare Therapeutics Inc. Common Shares (RPTX)
nasdaq.com - August 6 at 4:44 AM
Repare Therapeutics initiates early-stage study of RP-3500 in solid tumorsRepare Therapeutics initiates early-stage study of RP-3500 in solid tumors
seekingalpha.com - July 29 at 11:34 AM
Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500
finance.yahoo.com - July 29 at 6:34 AM
Morgan Stanley Says Buy Repare Therapeutics, Sees Nearly 60% UpsideMorgan Stanley Says Buy Repare Therapeutics, Sees Nearly 60% Upside
www.benzinga.com - July 16 at 9:57 AM
The Week Ahead In Biotech: J&J Kickstarts Pharma Earnings, Repare Therapeutics IPOThe Week Ahead In Biotech: J&J Kickstarts Pharma Earnings, Repare Therapeutics IPO
www.benzinga.com - July 12 at 12:57 PM
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.